US 11,911,392 B2
Non-catalytic substrate-selective p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
Paul S. Shapiro, Baltimore, MD (US); Alexander D. Mackerell, Jr., Baltimore, MD (US); and Jeffrey D. Hasday, Timonium, MD (US)
Assigned to UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD (US); and THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, Washington, DC (US)
Filed by University of Maryland, Baltimore, Baltimore, MD (US); and The United States of America as represented by the Department of Veterans Affairs, Washington, DC (US)
Filed on May 9, 2022, as Appl. No. 17/740,248.
Application 17/740,248 is a continuation of application No. 17/231,598, filed on Apr. 15, 2021, granted, now 11,357,781.
Application 17/231,598 is a continuation of application No. 16/312,499, abandoned, previously published as PCT/US2017/038697, filed on Jun. 22, 2017.
Claims priority of provisional application 62/469,913, filed on Mar. 10, 2017.
Claims priority of provisional application 62/353,856, filed on Jun. 23, 2016.
Prior Publication US 2022/0331329 A1, Oct. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5375 (2006.01); A61K 31/18 (2006.01); A61K 31/54 (2006.01); A61P 31/00 (2006.01); A61P 19/02 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/5375 (2013.01) [A61K 31/18 (2013.01); A61K 31/54 (2013.01); A61P 19/02 (2018.01); A61P 29/00 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01)] 20 Claims
 
1. A method of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein,
R5 is selected from —SO2—, —CH(OH)—, and —N(CH3)—; and
L1 is selected from —CH2—, —C(CH3)2—, and —C(CH2CH2)—,
wherein the disease is selected from rheumatoid arthritis, Alzheimer's disease, psoriasis, atherosclerosis, pain, multiple sclerosis, and glomerulosclerosis.